Worldwide obesity has more than doubled since 1980 with more than 600 million obese patients in 2014. Metabolic syndrome (MetS) is the co-occurrence of metabolic abnormalities, including centrally distributed obesity, hypertension, dyslipidemia, and hyperglycemia. With a concurrent rise in the incidence of kidney stone disease, we wanted to conduct a systematic review focused on the association of MetS to nephrolithiasis.
Materials and Methods:
A systematic review was performed according to the Cochrane and preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines on all English language articles for the following relevant keywords: association, metabolic syndrome, metabolic syndrome traits, syndrome X, nephrolithiasis, kidney stones, and renal calculi. Our inclusion criteria were studies comparing the prevalence of kidney stone disease in patients with and without MetS.
Results:
The initial literature search identified 355 potentially relevant studies. After screening, 22 full text articles were reviewed and 6 (219,255 patients) were included in the final review. All studies displayed increasing odds of nephrolithiasis with increasing number of MetS traits, where patients with three or more MetS traits tended to have a higher prevalence of nephrolithiasis. Studies also showed different significant components of MetS contributing to nephrolithiasis.
Conclusions:
Our review shows a definite association of MetS with kidney stone disease. Although multifactorial in etiology, lifestyle and dietary factors seem to be increasingly important in prevention of stone disease.
Get full access to this article
View all access options for this article.
References
1.
ZimmetP, MaglianoD, MatsuzawaY, AlbertiG, ShawJ. The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb, 2005; 12:295–300.
2.
EckelRH, GrundySM, ZimmetPZ. The metabolic syndrome. Lancet, 2005; 365:1415–1428.
3.
HammarstenJ, PeekerR. Urological aspects of the metabolic syndrome. Nat Rev Urol, 2011; 8:483–494.
4.
KendallDM, HarmelAP. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: Understanding the role of insulin resistance. Am J Manag Care, 2002; 8:S635–pS653; quiz S654–S657.
5.
RichmanK, O'BellJ, PareekG. The growing prevalence of kidney stones and opportunities for prevention. R I Med J (2013), 2014; 97:31–34.
6.
JohriN, CooperB, RobertsonW, ChoongS, RickardsD, UnwinR. An update and practical guide to renal stone management. Nephron Clin Pract, 2010; 116:c159–c171.
7.
LiberatiA, AltmanDG, TetzlaffJ, MulrowC, GotzschePC, IoannidisJPA, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ, 2009; 339:37.
8.
WestB, LukeA, Durazo-ArvizuRA, CaoG, ShohamD, KramerH. Metabolic syndrome and self-reported history of kidney stones: The National Health and Nutrition Examination Survey (NHANES III) 1988–1994. Am J Kidney Dis, 2008; 51:741–747.
9.
JeongIG, KangT, BangJK, ParkJ, KimW, HwangSS, et al.Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis, 2011; 58:383–388.
10.
JungHS, ChangIH, KimKD, MoonYT, KimTH, MyungSC, et al.Possible relationship between metabolic syndrome traits and nephrolithiasis: Incidence for 15 years according to gender. Korean J Urol, 2011; 52:548–553.
11.
KimY-J, KimC-H, SungE-J, KimS-R, ShinH-C, JungW-J. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism, 2013; 62:808–813.
12.
ChoST, JungSI, MyungSC, KimTH. Correlation of metabolic syndrome with urinary stone composition. Int J Urol, 2013; 20:208–213.
13.
GrundySM, BrewerHBJr., CleemanJI, SmithSCJr., LenfantC. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol, 2004; 24:e13–e18.
14.
FederspilG, NisoliE, VettorR. A critical reflection on the definition of metabolic syndrome. Pharmacol Res, 2006; 53:449–456.
15.
StoneNJ, RobinsonJG, LichtensteinAH, Bairey MerzCN, BlumCB, EckelRH, et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014; 129:S1–S45.
16.
Risk ICoC. Metabolic Syndrome and Type 2 Diabetes/CVD Risk. 2014. Available at www.myhealthywaist.org/evaluating-cmr/metabolic-syndrome-and-type-2-diabetescvd-risk/others/index.html (accessed November12, 2014).
17.
AlexanderCM, LandsmanPB, TeutschSM, HaffnerSM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 2003; 52:1210–1214.
18.
SirdahMM, Abu GhaliAS, Al LahamNA. The reliability of the National Cholesterol Education Program's Adult Treatment Panel III (NCEP/ATP III) and the International Diabetes Federation (IDF) definitions in diagnosing metabolic syndrome (MetS) among Gaza Strip Palestinians. Diabetes Metab Syndr, 2012; 6:4–8.
19.
Federation ID. The IDF consensus worldwide definition of metabolic syndrome. Available at www.idf.org/webdata/docs/Metac_syndrome_def.pdf. (accessed January10, 2015).
20.
AlbertiKGMM, ZimmetP, ShawJ. The metabolic syndrome—A new worldwide definition. Lancet; 366:1059–1062.
21.
SeidellJC. The worldwide epidemic of obesity. In: Guy-GrandB, AilhaudG, eds. Progress in Obesity Research, 8th ed. London: John Libbey, 1999, pp. 661–668.
22.
PopkinBM. Recent dynamics suggest selected countries catching up to US obesity. Am J Clin Nutr, 2010; 91:284S–288S.
23.
LeeS-C, KimY-J, KimT-H, YunS-J, LeeNK, KimW-J. Impact of obesity in patients with urolithiasis and its prognostic usefulness in stone recurrence. J Urol, 2008; 179:570–574.
24.
MosliHA, MosliHH, KamalWK. Kidney stone composition in overweight and obese patients: A preliminary report. Res Rep Urol, 2013; 5:11–15.
25.
AntonelliJA, MaaloufNM, PearleMS, LotanY. Use of the National Health And Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Eur Urol, 2014; 66:724–729.
26.
WagnerCA, MohebbiN. Urinary pH and stone formation. J Nephrol, 2010; 23Suppl 16:S165–S169.
27.
DomingosF, SerraA. Metabolic syndrome: A multifaceted risk factor for kidney stones. Scand J Urol, 2014; 48:414–419.
28.
StrohmaierWL, WrobelBM, SchubertG. Overweight, insulin resistance and blood pressure (parameters of the metabolic syndrome) in uric acid urolithiasis. Urol Res, 2012; 40:171–175.
29.
AbateN, ChandaliaM, Cabo-ChanAV, MoeOW, SakhaeeK. The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestation of insulin resistance. Kidney Int, 2004; 65:386–392.
30.
KadlecAO, GrecoK, FridiriciZC, HartST, VellosT, TurkTM. Metabolic syndrome and urinary stone composition: What factors matter most?. Urology, 2012; 80:805–810.
31.
SakhaeeK, CapolongoG, MaaloufNM, PaschA, MoeOW, PoindexterJ, et al.Metabolic syndrome and the risk of calcium stones. Nephrol Dial Transplant, 2012; 27:3201–3209.
YoonV, Adams-HuetB, SakhaeeK, MaaloufNM. Hyperinsulinemia and urinary calcium excretion in calcium stone formers with idiopathic hypercalciuria. J Endocrinol Metab, 2013; 98:2589–2594.
34.
RatkalkarVN, KleinmanJG. Mechanisms of stone formation. Clin Rev Bone Miner Metab, 2011; 9:187–197.
35.
AfsarB, KaracaH. The relationship between insulin, insulin resistance, parathyroid hormone, cortisol, testosterone, and thyroid function tests in the presence of nephrolithiasis: A comprehensive analysis. Cent European J Urol, 2014; 67:58–64.
36.
KohjimotoY, SasakiY, IguchiM, MatsumuraN, InagakiT, HaraI. Association of metabolic syndrome traits and severity of kidney stones: Results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis, 2013; 61:923–929.
37.
CupistiA, D'AlessandroC, SamoniS, MeolaM, EgidiMF. Nephrolithiasis and hypertension: Possible links and clinical implications. J Nephrol, 2014; 27:477–482.
38.
WeinbergAE, PatelCJ, ChertowGM, LeppertJT. Diabetic severity and risk of kidney stone disease. Eur Urol, 2014; 65:242–247.
39.
MastersonJH, WooJR, ChangDC, ChiT, L'EsperanceJO, StollerML, et al.Dyslipidemia is associated with an increased risk of nephrolithiasis. Urolithiasis, 2015; 43:49–53.
40.
HaymannJP, DaudonM, NormandM, HoznekA, MeriaP, TraxerO. [First-line screening guidelines for renal stone disease patients: A CLAFU update]. Prog Urol, 2014; 24:9–12.
41.
PearleMS, GoldfarbDS, AssimosDG, CurhanG, Denu-CioccaCJ, MatlagaBR, et al.Medical management of kidney stones: AUA guideline. J Urol, 2014; 192:316–324.
42.
Fernandez RodriguezA, Arrabal MartinM, Garcia RuizMJ, De Haro MunozT, Zuluaga GomezA. [Effect of thiazide therapy in the prophylaxis of calcium lithiasis]. Arch Esp Urol, 2001; 54:1047–1054.
43.
HuenSC, GoldfarbDS. Adverse metabolic side effects of thiazides: Implications for patients with calcium nephrolithiasis. J Urol, 2007; 177:1238–1243.
44.
TascaA. Metabolic syndrome and bariatric surgery in stone disease etiology. Curr Opin Urol, 2011; 21:129–133.
45.
CaseCC, JonesPH, NelsonK, O'Brian SmithE, BallantyneCM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab, 2002; 4:407–414.
46.
NoakesM, FosterPR, KeoghJB, CliftonPM. Meal replacements are as effective as structured weight-loss diets for treating obesity in adults with features of metabolic syndrome. J Nutr, 2004; 134:1894–1899.
47.
TorrisC, MolinM, Cvancarova SmastuenM. Fish consumption and its possible preventive role on the development and prevalence of metabolic syndrome—A systematic review. Diabetol Metab Syndr, 2014; 6:112.
48.
AnderssenSA, CarrollS, UrdalP, HolmeI. Combined diet and exercise intervention reverses the metabolic syndrome in middle-aged males: Results from the Oslo Diet and Exercise Study. Scand J Med Sci Sports, 2007; 17:687–695.
49.
World Health Organization (WHO). Obesity and overweight. Fact sheet N°311. Updated January2015. http://www/who.int/mediacentre/factsheets/fs311/en/ (accessed August5, 2015).
50.
SutherlandJW, ParksJH, CoeFL. Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab, 1985; 11:267–269.
51.
XuH, ZismanAL, CoeFL, WorcesterEM. Kidney stones: An update on current pharmacological management and future directions. Expert Opin Pharmacother, 2013; 14:435–447.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
